Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846581 | 0.90 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10782234 | 0.89 | SLC28A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1696779 | 0.89 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4390141 | 0.88 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4390144 | 0.88 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL23710653 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1585708 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL566228 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL123664 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL21275617 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117512038-A | Sansansamycin derivatives and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-06 | — | — | CN | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| CN-117512038-A | Sansansamycin derivatives and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-06 | — | — | CN | disclosed |
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | RNGTT, RNMT, UPF1 | SLC28A1 110/4885SLC28A2 60/4885SLC29A1 347/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC28A1 317/4885SLC28A2 259/4885SLC29A1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.